Author

Mohamed N. Fawzy

h-index 7 View on Semantic Scholar

We have 4 of 29 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Sep 2026

Resveratrol engages SIRT1/AMPK networks to restore BDNF signaling, autophagy, and mitochondrial function in age-related cognitive decline: A geroscience perspective.

Age-related cognitive decline and neurodegenerative disorders present significant challenges in neuropsychiatry, as current therapeutic strategies largely fail to adequately address the complexities of cerebral aging. Resveratrol, a natural polyphenol, has become a promising multi-target neuroprotective agent that can...

A. Al-Dhahi, Hayder M. Al-kuraishy, Mohamed N. Fawzy et al. · Progress in Neuro-psychophar... · 0 citations

Review Sep 2026

Targeting the α7-nicotinic acetylcholine receptor in multiple sclerosis: Implications for immunomodulation and neuroprotection.

By integrating immunomodulatory and neuroprotective actions, α7-nAChR targeting represents a mechanistically compelling strategy for comprehensive disease modification in MS, although clinical translation remains contingent upon overcoming significant pharmacological and biomarker-related challenges.

A. Al-Dhahi, Hayder M. Al-kuraishy, Ahmed A. Mohamed et al. · Life Science · 0 citations

Review Open access Jul 2026

Immunometabolic reprogramming in multiple sclerosis: from pathogenic amplifier to therapeutic target in neuroinflammation and remyelination

Multiple sclerosis (MS) has conventionally been considered a prototypical autoimmune disorder. While modern immunotherapies effectively control relapsing conditions, they fail to avert progressive neuroinflammation, neurodegeneration, and remyelination failure. This review offers an evidence-based recontextualization....

Ghada A. Badawi, Rehab M. El-Sayed, Mohamed N. Fawzy · InflammoPharmacology · 0 citations

Review Open access Aug 2026

The neuroimmune network in Alzheimer’s and Parkinson’s diseases: from mechanistic insights to biomarker-guided immunotherapies and clinical translation

A three-part biomarker framework, encompassing target engagement (CSF IL-1β, caspase-1), pharmacodynamic responses (neurofilament light chain, ASC specks), and predictive endotyping (T-cell clonality, complement profiles), is proposed to facilitate patient stratification by neuroimmune endotype.

Mohamed N. Fawzy · InflammoPharmacology · 0 citations